Search

Displaying results 6781 - 6790 of 10000 in total
  1. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    infusion between healthy adults and those with damaged livers) and NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a

  2. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

    Categories: Heterocyclic Compounds, 2-Ring, Receptors, Neurokinin-3, antagonists & inhibitors
  3. Drug

    Semaxanib

    go.drugbank.com/drugs/DB06436
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  4. Drug

    Tyloxapol

    go.drugbank.com/drugs/DB06439
    ApprovedInvestigational

    Tyloxapol is a non-ionic detergent often used as a surfactant.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Dexanabinol

    go.drugbank.com/drugs/DB06444
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    FK-960

    go.drugbank.com/drugs/DB06465
    Experimental

    Synonyms: N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamideCategories: Heterocyclic Compounds, 1-Ring
  7. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

    Synonyms: (SUB 1)-CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL HU1D10 LIGHT CHAIN, DIMER
  8. Drug

    Lestaurtinib

    go.drugbank.com/drugs/DB06469
    Investigational

    Categories: Cytochrome P-450 CYP3A Inhibitors, Heterocyclic Compounds, 1-Ring
  9. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.

  10. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    PW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.